CEVEC is a leading provider of high-performance cell technologies for the manufacturing of viral vectors for gene therapy and vaccine applications.
As a leading provider of high-performance cell technology for the manufacturing of advanced bio-therapeutics, CEVEC’s product portfolio comprises various platform technologies for gene therapy vectors and vector vaccines. ELEVECTA® is the technology of choice for AAV manufacturing. For RCA-free Adenoviral vectors, the CAP® Ad technology is the perfect fit.
Address
CEVEC Pharmaceuticals GmbH
Gottfried-Hagen-Str. 60
51105 Cologne
Germany
Phone: +49 221 46020800
Internet: www.cevec.com
With the ELEVECTA® Technology, CEVEC offers a unique solution for large-scale production of AAV vectors using helper virus-free producer cell lines with all necessary components stably integrated into the cell. The technology does not require any expensive transfection reagents or cGMP plasmids.
CEVEC’s CAP® Ad Technology based on proprietary human suspension cells is the production platform of choice for RCA-free adenoviral vectors. The platform design allows for easy scale-up and opens the way for various applications, from gene therapy to vaccine production.
With the ELEVECTA® Technology, CEVEC offers a unique solution for large-scale production of AAV vectors using helper virus-free producer cell lines with all necessary components stably integrated into the cell.
Click here if you notice an image that violates copyright or privacy rights.
We only use functionally necessary cookies and the web analysis tool Matomo in order to optimally design and continuously improve our website for you. By continuing to use our website, you agree to this. Further information and an objection possibility can be found here: Data protection